Research & Development

Pipeline

Scandion Oncology is building a pipeline of drugs that can revert cancer drug resistance through different mechanisms


Our Clinical Pipeline

Scandion Oncology has two programs in clinical development with our first-in-class lead compound SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is a clinical Phase II study. The second program, PANTAX, for the treatment of unresectable or metastatic pancreatic cancer is a clinical Phase Ib study.

Colorectal cancer
 
Pancreatic cancer
 

Our Pre-clinical Pipeline

Scandion Oncology is building a pre-clinical pipeline of drugs that can revert cancer drug resistance through different mechanisms, to increasingly broaden the offering of medicines able to combat various types of cancer drug resistance.

IMMUNO-ONCOLOGY
Multiple cancers
 
201
SCO-201
Solid tumors